首页 | 本学科首页   官方微博 | 高级检索  
     


Patent disclosure requirements for therapeutic antibody patents
Authors:Carmela De Luca  Anastassia Trifonova
Affiliation:1. Bereskin &2. Parr LLP, Life Sciences Group/Montreal and Toronto, Canada
Abstract:Introduction: Therapeutic antibodies have grown to become an important product class within the biopharmaceutical market. A prerequisite to their commercialization is adequate patent protection. Disclosure requirements and the types of claims available in different jurisdictions can impact the scope of protection available for antibodies.

Areas covered: A comparative review of statutory bases, patent office practices and selected decisions in Canada, the United States and the United Kingdom related to disclosure requirements is provided.

Expert opinion: Differences in disclosure requirements exist in different jurisdictions which can impact the type of claims obtained and their survival when attacked in litigation. Including a wide variety of claim types is a key strategy to ensuring therapeutic antibodies are adequately protected. Method of use claims may provide advantages and broader protection in some circumstances and should also be considered.

Keywords:Therapeutic antibodies  disclosure requirements  patent protection  support requirements  sufficiency  Canada  United States and United Kingdom
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号